MedTrace Logo

Efficacy of 12 Weeks Versus 24 Weeks Treatment of Directly Acting Antiviral Therapy in Patients With Hepatitis C Related Chronic Liver Disease

NCT07702396 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2026-07-14

No results posted yet for this study

Summary

This randomized controlled trial proposes to compare the treatment outcomes of 12 weeks versus 24 weeks of direct-acting antiviral (DAA) therapy in patients with HCV-related chronic liver disease, addressing the ongoing debate over the ideal treatment duration. To be conducted at the Department of Gastroenterology, Indus Hospital Health Network over nine months, the study will enroll 192 treatment-naive patients (96 per group) aged over 16 with chronic HCV, while excluding those with hepatocellular carcinoma, decompensated cirrhosis, other liver diseases, prior treatment failure, HBV/HIV co-infection, or various exclusionary lab parameters. Using consecutive sampling and draw randomization, Group A will receive 12 weeks and Group B will receive 24 weeks of a regimen comprising sofosbuvir, daclatasvir, and ribavirin, with all patients followed for 12 weeks post-treatment to assess the primary outcome of sustained virologic response (SVR, defined as HCV RNA \<25 IU/ml). Data will be analyzed in SPSS v25 using t-tests and chi-square tests, with a p-value ≤0.05 considered significant, ultimately aiming to determine whether 12 weeks of therapy is sufficient or whether extending to 24 weeks offers meaningful benefit.

Conditions

  • Heptatitis C

Interventions

OTHER

12 weeks Sofosbuvir 400 mg once daily, Daclatasvir 60 mg once daily, and Ribavirin 400 mg twice daily

The intervention is direct-acting antiviral (DAA) therapy using a combination of Sofosbuvir 400 mg once daily, Daclatasvir 60 mg once daily, and Ribavirin 400 mg twice daily, given for either 12 weeks.

Sponsors & Collaborators

  • Indus Hospital and Health Network

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-10
Primary Completion
2024-09-20
Completion
2024-09-20

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07702396 on ClinicalTrials.gov